TipRanks
Advertisement
Advertisement

DE:4AB Stock Latest News

AbbVie announces presentation of 22 scientific abstracts from IBD portfolio
The FlyAbbVie announces presentation of 22 scientific abstracts from IBD portfolio
2d ago
ABBV
AbbVie price target raised to $275 from $260 at UBS
PremiumThe Fly
AbbVie price target raised to $275 from $260 at UBS
4d ago
ABBV
AbbVie price target raised to $305 from $289 at BofA
PremiumThe Fly
AbbVie price target raised to $305 from $289 at BofA
4d ago
ABBV
AbbVie price target raised to $300 from $285 at JPMorgan
PremiumThe Fly
AbbVie price target raised to $300 from $285 at JPMorgan
5d ago
ABBV
AbbVie price target raised to $290 from $285 at Cantor Fitzgerald
PremiumThe Fly
AbbVie price target raised to $290 from $285 at Cantor Fitzgerald
5d ago
ABBV
AbbVie price target raised to $310 from $296 at Morgan Stanley
PremiumThe FlyAbbVie price target raised to $310 from $296 at Morgan Stanley
6d ago
ABBV
AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations
Premium
The Fly
AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations
6d ago
ABBV
AbbVie price target raised to $320 from $280 at Scotiabank
Premium
The Fly
AbbVie price target raised to $320 from $280 at Scotiabank
7d ago
ABBV
AbbVie sees Q3 EPS $3.73-$3.77, consensus $3.84
PremiumThe Fly
AbbVie sees Q3 EPS $3.73-$3.77, consensus $3.84
8d ago
ABBV
AbbVie sees FY26 EPS $13.76-$13.96, consensus $14.01
PremiumThe Fly
AbbVie sees FY26 EPS $13.76-$13.96, consensus $14.01
8d ago
ABBV
Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study
PremiumThe Fly
Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study
8d ago
ABBV
GMAB
AbbVie presents long-term RINVOQ data at EADV Congress
PremiumThe Fly
AbbVie presents long-term RINVOQ data at EADV Congress
12d ago
ABBV
AbbVie reports Phase 1 data for ABBV-295
PremiumThe FlyAbbVie reports Phase 1 data for ABBV-295
13d ago
ABBV
AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart
Premium
The Fly
AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart
13d ago
ABBV
AbbVie partners with Valkai to apply advanced AI across clinical development
Premium
The Fly
AbbVie partners with Valkai to apply advanced AI across clinical development
14d ago
ABBV
Ginkgo Bioworks, Apheris announce kick off of Antibody Developability Consortium
PremiumThe Fly
Ginkgo Bioworks, Apheris announce kick off of Antibody Developability Consortium
14d ago
DNA
TAK
AbbVie price target raised to $289 from $282 at BofA
PremiumThe Fly
AbbVie price target raised to $289 from $282 at BofA
14d ago
ABBV
AbbVie announces FDA approval of Juvmo to treat Parkinson’s disease
PremiumThe Fly
AbbVie announces FDA approval of Juvmo to treat Parkinson’s disease
15d ago
ABBV
Analyst Reaffirms Buy Rating on AbbVie, Maintaining $280 Price Target After Strong CERVINO Phase III Data
PremiumRatings
Analyst Reaffirms Buy Rating on AbbVie, Maintaining $280 Price Target After Strong CERVINO Phase III Data
15d ago
ABBV
AbbVie: EC approves Rinvoq to treat polyarticular juvenile idiopathic arthritis
PremiumThe FlyAbbVie: EC approves Rinvoq to treat polyarticular juvenile idiopathic arthritis
21d ago
ABBV
AbbVie, Iambic announce multi-year collaboration
Premium
The Fly
AbbVie, Iambic announce multi-year collaboration
22d ago
ABBV
AbbVie presents new Vraylar data at Psych Congress 2026
Premium
The Fly
AbbVie presents new Vraylar data at Psych Congress 2026
25d ago
ABBV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >